The vision for a new diagnostic paradigm

Clinical Chemistry

Volumn 49, Issue 8, 2003, Pages 1276-1278

  Petricoin III, Emanuel ^a   Liotta, Lance A ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROTEIN;

CANCER DIAGNOSIS; CANCER SCREENING; DIAGNOSTIC TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR WEIGHT; OVARY CANCER; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; TECHNOLOGY; VALIDATION PROCESS; BLOOD; DIAGNOSIS, MEASUREMENT AND ANALYSIS; LABORATORY; NOTE; STANDARD;

BIOLOGICAL MARKERS; HUMANS; LABORATORIES; LABORATORY TECHNIQUES AND PROCEDURES; MASS SPECTROMETRY; PROTEINS; PROTEOMICS; SENSITIVITY AND SPECIFICITY;

EID: 0042868833     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/49.8.1276     Document Type: Review

References (12)

1. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845-67.
2. Ward JB Jr, Henderson RE. Identification of needs in biomarker research [Review]. Environ Health Perspect 1996;5(104 Suppl):895-900.
3. Petricoin EF III, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.
4. Petricoin EF III, Liotta LA. Mass spectrometry-based diagnostics: the upcoming revolution in disease detection [Editorial]. Clin Chem 2003;49:533-4.
5. Adam BL, Vlahou A, Semmes OJ, Wright GL Jr. Proteomic approaches to biomarker discovery in prostate and bladder cancers [Review]. Proteomics 2001;1:1264-70.
6. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296-304.
7. Petricoin EF 3rd, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002;94:1576-8.
8. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62:3609-14.
9. Chase DH. Mass spectrometry in the clinical laboratory. Chem Rev 2001;101:445-77.
10. Chase, Kalas TA, Naylor EW. The application of tandem mass spectrometry to neonatal screening for inherited disorders of intermediary metabolism. Annu Rev Genomics Hum Genet 2002;3:17-45.
11. Diamandis EP, Scorilas A, Fracchioli S, Van Gramberen M, De Bruijn H, Henrik A, et al. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol 2003;21:1035-43.
12. Kim JH, Skates SJ, Uede T, Wong Kk KK, Schorge JO, Feltmate CM, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002;287:1671-9.